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Isovalerylglycine as biomarker for the predisposition for weight gain and obesity 
The present invention relates generally to the field of nutrition and health. In 
particular, the present invention relates to a new biomarker, its use and a method 
5 that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to 
be susceptible to a diet induced weight gain. For example, the biomarker may be 
isovalerylglycine. This biomarker may also be used for diagnosing/monitoring the 
effect of a change in lifestyle on weight gain risk in a subject. 
10 Obesity has become one of the most important global healthcare problems in the 
21st century as it raises the risk to develop further diseases including type 2 diabetes, 
hepatic steatosis (NAFLD), cancers, arthritis and cardiovascular diseases (CVD). The 
aetiology of obesity results from a complex interaction between genetic and 
environmental factors such as high caloric diet, lack of physical activity and 
15 behaviour. Gut microbiota being involved in various physiological functions such as 
the maturation of gut's innate immune system and the digestion/absorption of 
nutrients also influences the development of several metabolic diseases and seem to 
have a significant impact on obesity. Hence, individual predisposition of developing 
obesity varies according to these multi-factorials causes. 
20 
Ingestion of an unbalanced diet rich in fat and/or carbohydrate has been associated 
with an increased rate of triglyceride storage in adipose tissues as well as lean tissues 
such as liver, muscle and heart. This ectopic fat deposition inducing lipotoxicity is 
also correlated with a range of metabolic disorders such as hypertriglyceridemia, 
25 hypertension, high fasting glucose and insulin resistance (IR). Nonetheless, some 
overweight or obese people may develop various metabolic disorders and while 
others stay healthy. For instance, the localisation of fat deposition in the body 
influences the development of metabolic disorders. Epicardial fat, being efficient to 
release proatherogenic adiponectines and process fatty acids, has been positively 
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correlated with CVD markers in humans. By contrast, intra-hepatic fat has been 
associated with inflammation and insulin resistance. Wildman et al. also highlighted 
that race-ethnic differences in healthy middle age women are associated with 
differential metabolic activity of visceral and subcutaneous adipose tissues which 
5 could influence the ethnic-related predisposition to develop obesity and CVD]. As a 
result, it is relevant to identify the likelihood to develop obesity-related metabolic 
disorders at an early stage, in order to assess the individual metabolic status and to 
effectively prevent the development of metabolic diseases. 
10 It would therefore be desirable to provide the art with a method that allows it to 
identify subjects early - ideally before they put on weight - that are likely gain weight 
when consuming diets rich in fats. 
Any reference to prior art documents in this specification is not to be considered an 
15 admission that such prior art is widely known or forms part of the common general 
knowledge in the field. 
The object of the present invention is to improve the state of the art and in particular 
to provide a method that allows it to effectively stratify people early whether or not 
20 they are likely to respond to a high fat diet with weight gain. 
25 
The inventors were surprised to see that the object of the present invention could be 
achieved by the subject matter of the independent claims. The dependent claims 
further develop the idea of the present invention. 
Accordingly, the present invention provides a biomarker, its use and a method for 
diagnosing the likelihood to resist a high fat diet induced weight gain. 
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As used in this specification, the words "comprises", "comprising", and similar words, 
are not to be interpreted in an exclusive or exhaustive sense. In other words, they 
are intended to mean "including, but not limited to". 
5 The inventors have used a metabonomics approach to achieve the objective of the 
present invention. Metabonomics is considered today a well-established system 
approach to characterize the metabolic phenotype, which comprises the influence of 
various factors such as environment, drugs, diet, lifestyle, genetics, and microbiome 
factors. Unlike gene expression and proteomic data that indicate the potential for 
10 physiological changes, metabolites and their dynamic concentration changes within 
cells, tissues and organs, represent the real end-points of physiological regulatory 
processes. 
It is therefore a suitable approach to investigate the gradual metabolic changes linked 
15 to various dietary interventions and diseases development. Recently, metabolomics 
and lipidomics-based discoveries have been accelerating our understanding of 
disease processes, and will provide novel avenues for prevention and nutritional 
management of the sub-clinical disorders associated to metabolic syndrome. In 
particular, "omics" data have highlighted the contribution of energy metabolism 
20 (Krebs's cycle), lipid and amino acid processing, as well as inflammatory signals to the 
onset of obesity and insulin resistance (IR). 
Using a combination of proton nuclear magnetic resonance (lH NMR) spectroscopy of 
urine samples collected overtime and weight gain monitoring, the inventors have 
25 identified novel metabolic biomarkers of gradual weight gain induced by a high fat 
diet in a well defined C57BL/6 mouse model. This animal model is well known to 
show extreme phenotypes across isogenic animals, i.e. animals resistant or prone to 
high fat induced weight gain distribution. The present inventors have characterised 
the short term (7 day) and long term (60 day) metabolic adaptation of C57BL/6 mice 
3 
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fed with a high fat diet (HFD) and have established the specific metabolic signatures 
associated with phenotype variability within HFD fed mice, i.e. animals resistant or 
prone to high fat induced weight gain. By using a metabonomic approach, the 
inventors have showed that mitochondrial metabolic pathways (fatty acid ~ 
5 oxidation, branched-chain amino acid catabolism, butanoate metabolism, 
nicotinamide adenine dinucleotide pathway and Krebs's cycle) are quickly up-
regulated by high fat feeding which might reflect a fatty acid saturation of 
mitochondria and an impairment of energy metabolism. 
10 The inventors could show that obesity resistant mice under HFD are associated with a 
specific activation of mitochondrial oxidative pathways (~ oxidation, butanoate 
metabolism and leucine catabolism) which may be a protective mechanism against 
fatty acid overloading. 
15 These results emphasize the role of mitochondria in obesity development and allows 
the conclusion that the likelihood to develop metabolic disorders, such as obesity, 
can be determined from an early metabolic signature using a specific set of 
biomarkers that the inventors have identified. 
20 The inventors were able to show that the urine metabolic response after one week 
on high fat feeding (Day 7) enables not only the prediction of the final weight gain for 
each individual (Day 60), but also to stratify animals according to their predisposition 
to be resistant or prone to high fat induced weight gain. 
25 Consequently, the present invention relates to a novel biomarker, isovalerylglycine. 
The invention further relates to the use of isovalerylglycine as a biomarker in urine 
for detecting and/or quantifying the likelihood to resist high fat diet induced weight 
gain. 
4 
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Similarly, the invention also relates to the use of isovalerylglycine as a biomarker in 
urine for detecting and/or quantifying the likelihood to be susceptible to high fat diet 
induced weight gain. 
5 The invention also relates to a method of diagnosing the likelihood to resist high fat 
diet induced weight gain in a subject, comprising determining the level of 
isovalerylglycine in a urine sample previously obtained from a subject to be tested, 
and comparing the subject's isovalerylglycine level to a predetermined reference 
value, wherein the predetermined reference value is based on an average 
10 isovalerylglycine level in urine in a control population, and wherein an increased 
isovalerylglycine level in the sample compared to the predetermined reference value 
indicates an increased likelihood to resist high fat diet induced weight gain. Similarly, 
the invention also relates to a method of diagnosing the likelihood be susceptible to 
high fat diet induced weight gain in a subject, comprising determining the level of 
15 isovalerylglycine in a urine sample previously obtained from a subject to be tested, 
and comparing the subject's isovalerylglycine level to a predetermined reference 
value, wherein the predetermined reference value is based on an average 
isovalerylglycine level in urine in a control population, and wherein a decreased 
isovalerylglycine level or the absence of change in the sample compared to the 
20 predetermined reference value indicates a increased likelihood to be susceptible to 
high fat diet induced weight gain. 
This biomarker of the present invention may also be used for diagnosing and/or 
monitoring the effect of a change in lifestyle on weight gain risk in a subject. For this 
25 the biomarker level may be assessed before the lifestyle change and the resulting 
level may be compared to the level of the said biomarker after the lifestyle change. 
Figure 1: Variability of body weight gain in a population of n=56 mice fed a HFD. (A) 
Experimental design. (B) Body weight distribution of mice after 7 days and 60 days of 
5 
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HFD feeding. (C) Identification of non-responder (NR) and strong responder (SR) mice 
to obesity at each time-point. Several NR and SR mice are observed in 2 time points 
or during the overall course of the experiment. (D) Weight monitoring of control 
(n=24), NR (n=30), and SR (n=29) mice before the diet (to), after 7days (tl) and 60 
5 days (t2), of HFD feeding. s(n=average ± standard error, p value for non parametric 
Mann and Whitney test *<0.05, **<0.001, ***<0.0001.) 
Figure 2: IH NMR urine metabolic profile of C57BL/6 HFD fed or LFD fed mice 7 days 
and 60 days after the diet switch. (A) Mean IH NMR spectrum of urine from LFD fed 
10 mice or (B) HFD fed mice. (C) OPLS-DA score plot of urine metabolic profile of LFD 
and HFD fed mice at 7 days (D) OPLS-DA score plot of urine metabolic profile of LFD 
and HFD fed mice at 60days. (E) Heatmap obtained from the OPLS-DA coefficient 
plots showed metabolites found to be significantly different in HFD and LFD fed mice. 
Correlation values of the metabolites are displayed by color code. (Gradient of red 
15 color for metabolites positively correlated with HFD-fed mice and gradient of blue 
colors for metabolites negatively correlated). 
Figure 3: Specific metabolic signature of NR and SR mice. (A) Mean of IH NMR spectra 
of urine from NR mice or (B) SR mice. (C) OPLS-DA score plot of urine metabolic 
20 profile of NR and SR mice at 7 days (D) and 60days. (E) Heatmap obtained from the 
OPLS-DA coefficient plots showed metabolites found to be significantly different in 
NR and SR mice. Correlation values of the metabolites are displayed by color code. 
(Gradient of red color for metabolites positively correlated with SR mice and gradient 
of blue colors for metabolites negatively correlated). 
25 
Figure 4: Mapping of the urinary excretion pattern of metabolites involved in BCAAs, 
butanoate, Nicotinamide adenine dinucleotide metabolism, Krebs's cycle and ~ 
oxidation. The bar plots showed the mean ratio with standard error of metabolite 
integrals at day 7 to day 0 or day 60 to day O. The Y axis indicates the value of the 
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mean for LF, HF,NR and SR mice (arbitrary unit). Significant difference between mean 
ratios of LF and HF or NR and SR were calculated with non parametric Mann Whitney 
test: * <0.05, **<0.001, ***<0.0001 (values of mean, standard errors and p value in 
supplementary tables 3 and 4). Indirect metabolic reactions are highlighted with 
5 dash arrows. 
Figure 5 shows metabolite importance and robustness in predicting NR and SR as 
assessed by Random forest analysis. 
10 Table 1: Summary of relationships between metabolites and weight gain in high fat 
induced weight gain 
15 
Table 2: Summary of the fold of changes in selected metabolites over time in weight 
gain resistant (NR)and prone (SR) individuals 
The present invention relates in part to a biomarker, wherein the biomarker is 
isova lerylglyci ne. 
In the experiments described herein, mice fed with a HFD displayed a urinary increase 
20 of isovalerylglycine over time. Without wishing to be bound by theory, the inventors 
currently believe that the increase of several Krebs's cycle intermediates and end-
products of nicotinamide adenine dinucleotide pathways in urine of HFD mice may be 
considered evidence for energy over-production in mitochondria. The chronic 
increase of mitochondria oxidative pathways are considered to be deleterious for the 
25 mitochondria leading to impairment of oxidative pathways and of energy 
metabolism. In addition, the excess of free fatty acids can be stored as triglycerides in 
adipose tissues as well as in lean tissues which may promote organ dysfunction and 
metabolic diseases such as hepatic steatosis or cardiovascular diseases. 
7 
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The inventors have found that isovalerylglycine may be used as a biomarker in a body 
fluid for detecting and/or quantifying the likelihood to resist high fat diet induced 
weight gain. The body fluid may be urine. Using urine as body fluid has the advantage 
that it can be obtained regularly, non-invasively and without the support of medical 
5 person nel. 
This diagnostic method is practiced outside of the human or animal body. Typically, 
the biomarker detection and/or quantification step is carried out in a body fluid 
sample that was previously obtained from the subject to be tested. 
10 While the present invention is described in view of quantifying the likelihood to resist 
high fat diet induced weight gain, it is clear to skilled artesians that the same method 
can be also used for quantifying the likelihood to be susceptible to a high fat diet 
induced weight gain. Skilled artesians understand that if an increased level of a 
biomarker is indicative for an increased likelihood to resist high fat diet induced 
15 weight gain, a decreased level of a biomarker is indicative for an increased likelihood 
to be susceptible to a high fat diet induced weight gain, and vice versa. 
Hence the present invention also related to the use of isovalerylglycine as a 
biomarker in urine for detecting and/or quantifying the likelihood to be susceptible to 
20 high fat diet induced weight gain. 
The present invention also relates to a method of diagnosing the likelihood of a 
subject to resist high fat diet induced weight gain, comprising determining the level 
of isovalerylglycine in a urine sample previously obtained from a subject to be tested, 
25 and comparing the subject's isovalerylglycine level to a predetermined reference 
value, wherein the predetermined reference value is based on an average 
isovalerylglycine level in urine in a control population, and wherein an increased 
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isovalerylglycine level in the sample compared to the predetermined reference value 
indicates an increased likelihood to resist high fat diet induced weight gain. 
The present invention also relates to a method of diagnosing the likelihood of a 
5 subject to be susceptible to high fat diet induced weight gain, comprising determining 
the level of isovalerylglycine in a urine sample previously obtained from a subject to 
be tested, and comparing the subject's isovalerylglycine level to a predetermined 
reference value, wherein the predetermined reference value is based on an average 
isovalerylglycine level in urine in a control population, and wherein a decreased 
10 isovalerylglycine level in the sample compared to the predetermined reference value 
indicates an increased likelihood to be susceptible to high fat diet induced weight 
gain. 
Using urine as sample has the advantage that in can be obtained non-invasively using 
15 a well established procedure. The actual diagnosis method is then carried out outside 
the body. 
The level of isovalerylglycine in the sample can be detected and quantified by any 
means known in the art. For example, IH-NMR, mass spectroscopy, e.g, UPLC-ESI-
20 MS/MS, may be used. Other methods, such as other spectroscopic methods, 
chromatographic methods, labeling techniques, or quantitative chemical methods 
may be used as well. Ideally, the isovalerylglycine level in the sample and the 
reference value are determined by the same method. 
25 The predetermined reference value may be based on an average isovalerylglycine 
level in the tested body fluid in a control population. The control population can be a 
group of at least 3, preferably at least 10, more preferred at least 50 people with a 
similar genetic background, age and average health status. 
9 
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The present invention allows it, for example, to stratify subjects early, before they 
put on weight which may result in health risks. By being aware whether one is 
susceptible to high fat diet induced weight gain, one can adjust lifestyle and diet 
accordingly early. An appropriate lifestyle, ideally accompanied by a personalized 
5 nutritional regime allows it to maintain a healthy physique and avoids that one has to 
make significant efforts in terms of caloric restrictions and/or exercise regimens to 
regain that healthy physique. 
While isovalerylglycine as sole marker is effective as a tool for the diagnosis method 
10 of the present invention, the quality and/or the predictive power of said diagnosis 
will be improved, if the diagnosis relies on more than just one marker. 
Hence one or more other markers for diagnosing an increased likelihood to resist 
high fat diet induced weight gain and/or for diagnosing an increased likelihood to be 
15 susceptible to high fat diet induced weight gain may be used in combination with 
isova le rylglyci ne. 
The inventors were surprised to see that also other biomarkers can be used to detect 
an increased likelihood to resist high fat diet induced weight gain and/or for 
20 diagnosing an increased likelihood to be susceptible to high fat diet induced weight 
gain. 
As such the inventors have identified that increased urine concentrations of 
hexanoylglycine, leucine, isobutyrate, acetate, and decreased urine concentrations of 
25 trimethylamine-N-oxide, guanidoacetate, sucrose, tartaric acid, hippuric acid and 
hydroxyphenylacetylglycine allow diagnosing an increased likelihood to resist high fat 
diet induced weight gain. 
10 
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The methods of the present invention may, hence, further comprise the steps of 
determining the level of at least one further biomarker selected from the group 
consisting of hexanoylglycine, trimethylamine-N-oxide, leucine, isobutyrate, acetate, 
guanidoacetate, sucrose, tartaric acid, hippuric acid and hydroxyphenylacetylglycine 
5 in the urine sample, and comparing the subject's level of the at least one further 
biomarker to a predetermined reference value, wherein the predetermined 
reference value is based on average levels of that at least one further biomarker in a 
urine sample of a normal healthy control population, and wherein an increased 
hexanoylglycine, leucine, isobutyrate, acetate, and a decreased trimethylamine-N-
10 oxide, guanidoacetate, sucrose, tartaric acid, hippuric acid and/or 
hydroxyphenylacetylglycine level in the urine sample compared to the predetermined 
reference values indicates an increased likelihood to resist high fat diet induced 
weight gain. Accordingly, a decreased hexanoylglycine, leucine, isobutyrate, acetate, 
and an increased trimethylamine-N-oxide, guanidoacetate, sucrose, tartaric acid, 
15 hippuric acid and/or hydroxyphenylacetylglycine level in the urine sample compared 
to the predetermined reference values indicates an increased likelihood to be 
susceptible to high fat diet induced weight gain. 
Also the further biomarkers may be detected and quantified by IH-NMR or mass 
20 spectroscopy, e.g, UPLC-ESI-MS/MS. Other methods, such as other spectroscopic 
methods, chromatographic methods, labeling techniques, or quantitative chemical 
methods may be used as well. 
Ideally, all assessed biomarkers are assessed by the same technology. They may be 
25 assessed simultaneously. 
For example, isovalerylglycine may be assessed together with trimethylamine-N-
oxide. 
Isovalerylglycine may also be assessed together with hexanoylglycine. 
11 
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Isovalerylglycine may also be assessed together with leucine. 
Isovalerylglycine may also be assessed together with acetate. 
PCT/EP2013/074570 
Isovalerylglycine may also be assessed together with trimethylamine-N-oxide and 
hexanoylglycine. 
5 Isovalerylglycine may also be assessed together with trimethylamine-N-oxide, 
hexanoylglycine, and leucine. 
Isovalerylglycine may also be assessed together with trimethylamine-N-oxide, 
hexanoylglycine, and acetate. 
Isovalerylglycine may also be assessed together with trimethylamine-N-oxide, 
10 hexanoylglycine, acetate, and leucine. 
15 
Isovalerylglycine may also be assessed together with trimethylamine-N-oxide, 
hexanoylglycine, acetate, leucine, and guanidoacetate. 
Isovalerylglycine may also be assessed together with trimethylamine-N-oxide, 
hexanoylglycine, acetate, leucine, guanidoacetate and hippuric acid. 
The advantage of assessing more than one biomarker is that the more biomarkers are 
evaluated the more reliable the diagnosis will become. If, e.g., more than 1, 2, 3,4, 5, 
6, or 7 biomarkers exhibit the elevations or decreases in concentration as described 
above, the predictive power for detecting and/or quantifying the likelihood to resist 
20 and/or be susceptible to high fat diet induced weight gain is stronger. 
The reference value for isovalerylglycine and optionally for the other biomarkers is 
preferably measured using the same units used to characterize the level of 
isovalerylglycine and optionally the other biomarkers obtained from the test subject. 
25 Thus, if the level of the isovalerylglycine and optionally the other biomarkers is an 
absolute value such as the units of isovalerylglycine in IJ.mol/1 (IJ.M) the reference 
value is also based upon the units of isovalerylglycine in IJ.mol/1 (IJ.M) in individuals in 
the general population or a selected control population of subjects. 
12 
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Moreover, the reference value can be a single cut-off value, such as a median or 
mean. Reference values of isovalerylglycine and optionally the other biomarkers in 
obtained body fluid samples, such as mean levels, median levels, or "cut-off" levels, 
may be established by assaying a large sample of individuals in the general 
5 population or the selected population and using a statistical model such as the 
predictive value method for selecting a positivity criterion or receiver operator 
characteristic curve that defines optimum specificity (highest true negative rate) and 
sensitivity (highest true positive rate) as described in Knapp, R. G., and Miller, M. C. 
(1992). Clinical Epidemiology and Biostatistics. William and Wilkins, Harual Publishing 
10 Co. Malvern, Pa., which is incorporated herein by reference. 
Skilled artesians will know how to assign correct reference values as they will vary 
with gender, race, genetic heritage, health status or age, for example. 
15 In the method of the present invention, a decreased likelihood to resist high fat diet 
induced weight gain is indicative for the likelihood to develop disorders associated 
with overweight and/or obesity. 
"Overweight" is defined for an adult human as having a BMI between 25 and 30. 
20 "Body mass index" or "BMI" means the ratio of weight in kg divided by the height in 
metres, squared. "Obesity" is a condition in which the natural energy reserve, stored 
in the fatty tissue of animals, in particular humans and other mammals, is increased 
to a point where it is associated with certain health conditions or increased mortality. 
"Obese" is defined for an adult human as having a BMI greater than 30. 
25 
Disorders associated with overweight and/or obesity may be cardio metabolic 
diseases and/or metabolic deregulations. 
13 
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The method of the present invention allows it for example to determine the degree 
of susceptibility of subjects to diet induced weight gain. The method may hence allow 
stratifying patients according to their likelihood to put on weight based on a high 
caloric - in particular high fat - diet, independently from whether they are presently 
5 underweight, normal, overweight or obese. Adult people are considered underweight 
if they have a BMI equal to or less than 18.5. 
The method of the present invention may also be carried out in underweight, normal, 
overweight or in obese subjects. In particular in underweight, overweight or in obese 
subjects the method of the present invention may help to elucidate the genetic 
10 predisposition of the subject. Based thereon - and ideally under further consideration 
of their general health status and lifestyle - personalized nutritional regimens may be 
developed, that can help to maintain or regain a healthy status. 
The method of the present invention is not limited to humans. It may also be used in 
animals, such as companion animals, for example. Companion animals, such as cats 
15 or dogs may be analyzed. Based thereon nutritional regimens may be designed that 
will contribute to a long life of the companion animal in good health. 
The study presented in this application provides insight in the physiological 
mechanisms related to HF (high fat) induced obesity development and particularly 
highlights the specific metabolic adaptations associated to obese phenotype 
20 variability. High fat ingestion provokes a rapid and consistent up-regulation of 
mitochondrial metabolic pathways resulting in more production of energy and 
increased mitochondrial fatty acid saturation. Among the HF fed mice, obesity-
resistant (NR) mice were identified, which particularly activated specific 
mitochondrial metabolic pathways (~ oxidation, butanoate metabolism and leucine 
25 catabolism) and seemed to maintain energy homeostasis (activity of Krebs's cycle 
comparable to LFD). The inventor's results hence suggest that a specific activation of 
mitochondrial oxidative pathways might enable to conserve energy homeostasis and 
14 
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protect mitochondria against fuel overloading. Therefore, the role of mitochondria 
seems to be crucial in the development of obesity and its associated metabolic 
disorders. Consequently, this comprehensive analysis of the mechanisms underlying 
heterogeneous adaptation to HFD feeding provides novel and promising perspectives 
5 for weight management programs and personalized nutritional solutions. 
Hence, if the method of the present invention allows identifying a decreased 
likelihood to resist high fat diet induced weight gain - or an increased likelihood to be 
susceptible to high fat diet induced weight gain - this may be indicative for a lack of 
specific activation of mitochondrial oxidative pathways. 
10 Conversely, if the method of the present invention allows identifying an increased 
likelihood to resist high fat diet induced weight gain- or a decreased likelihood to be 
susceptible to high fat diet induced weight gain - this may be indicative for a specific 
activation of mitochondrial oxidative pathways. 
The mitochondrial oxidative pathways may be selected from the group consisting of ~ 
15 oxidation, butanoate metabolism and leucine catabolism. 
As the method of the present invention allows the stratification of subject without 
the need to have the symptoms of predispositions visible, it is for example suitable 
for children, teenagers, young adults and/or a subjects at risk of developing 
overweight or obesity. 
20 Through awareness, such a risk can be suitably met in terms of diet and lifestyle and 
the possible risks that may be derived from overweight or obesity later in life can be 
eliminated. 
Hence, the method may be used to devise a stratified diet for a specific group of 
subjects or a personalized diet for a specific subject. 
15 
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Those skilled in the art will understand that they can freely combine all features of 
the present invention disclosed herein. In particular, features described for the use of 
5 the present invention may be combined with the method of the present invention 
and vice versa. Further, features described for different embodiments of the present 
invention may be combined. 
Although the invention has been described by way of example, it should be 
10 appreciated that variations and modifications may be made without departing from 
the scope of the invention as defined in the claims. 
Furthermore, where known equivalents exist to specific features, such equivalents 
are incorporated as if specifically referred in this specification. Further advantages 
15 and features of the present invention are apparent from the figures and non-limiting 
examples. 
Examples: 
20 Animal handling procedure and sample preparation: 
The experiment was carried out under appropriate national guidelines at the Nestle 
Research Center (NRC, Switzerland). The mice were maintained in individual cage 
under 12h-12h of light-dark regime and fed ad libitum during the overall experiment. 
A total of 80 C57BL/6 mice firstly received a standard CHO (Baseline 3437,) for several 
25 weeks and a first collection of urine was carried out following this treatment (to). 
Mice were then split in 2 groups: 24 mice were fed with a different CHO (Low Fat 
012450B, composition see supplementary figures) in which the rate of protein, 
vitamins, minerals and carbohydrates was different from the first standard diet. 56 
other mice were fed with HFO (High Fat 012492) in which the dietary composition 
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apart from the level of carbohydrate and fat, were comparable to the second CHD. 
These two groups were respectively characterized as control groups and DIO groups. 
Once again, urine samples were collected 7 days (tl) and 60 days (t2) after the diet 
switch. All the samples were snap-frozen at -80 C until analysis. All mice were also 
5 weight at to, tl, t2 in order to monitor the weight gain in both HFD and control 
groups. Difference in weight gain of HFD and LFD as well as NR and SR was assessed 
by non parametric test (Wilcoxon-Mann-Whitney U test). Food intake (FI) of each 
mouse was also recorded at tl and t2. There is a significant decrease of FI in HFD fed 
mice compared to LFD fed mice overtime. SR mice also have higher FI than NR mice 
10 at both time points. The difference of FI between groups was calculated by Wilcoxon-
Mann-Whitney U test. 
lH NMR spectroscopy 
A volume of 40 IJ.I of urine were diluted in 20 IJ.I of buffer solution (NaHP04, 0.6M 
15 pH=7) containing sodium azide (3 mM) and TSP (0.5 mM). After centrifugation, 
samples were transferred in 1.7 mm diameter NMR tubes by using a syringe. lH NMR 
spectra were then recorded on 600.13 MHz spectrometer, by performing 64 scans of 
a standard sequence with 64K data-points. The temperature of NMR experiment was 
maintained at 300 K. Processing of urine spectra was carried out by using the 
20 software TOPSPIN 2.0 (Bruker Biospin, Rheinstetten, Germany). For each spectrum, 
the FIDs were multiplied by an exponential function corresponding to a line 
broadering of 1 Hz, prior to being transformed into spectrum by a Fourrier 
Transformer. The phase and baseline of the spectra were then manually corrected. 
The chemical shift was calibrated by using the TSP signal at l5 O. Spectral assignments 
25 were achieved by using STOCSY (Statistical TOtal Correlation SpectroscopY), spectral 
databases and published assignment 
Data processing and multivariate data analysis: 
17 
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The spectral data (from 6 0.2 to 6 9.5) were finally imported into Matlab software 
(version, the mathworks Inc, Natwick MA) and were transformed into 22K data-
points. Resonance of water peak (6 4.7-5.05) was removed from each spectrum in 
order to eliminate the variability linked to the water resonance presaturation. lH 
5 NMR spectra were then normalized on total area and different multivariate statistics 
(PCA, OPLS, and OPLS-DA) were applied by using "unit variance" scaling. the OPLS 
regression coefficient can be displayed using a back-scaling method. In this way, we 
can estimate the proportion of variance of each NMR variable responsible for group 
discrimination in the model. The construction of heatmaps showing metabolites with 
10 highest coefficient values provides an easy comparison of short term and long term 
metabolic responses to HFD feeding. Heatmaps were generated by taking the values 
of the correlation coefficient of metabolites discriminating HFD/LFD or SR/NR. 
Correlation coefficients above the cutoff of 0.3 are displayed by a color map 
(gradients from red to blue according to the value of covariance in each metabolite) 
15 Hence heatmaps provide an easy comparison of the short term and long term 
metabolic responses to obesity development. 
Univariate data analysis 
Intermediates metabolites from beta oxidation, BCAAs oxidation, Krebs's cycle and 
20 Nicotinamide adenine dinucleotide pathways assignable on urine lH NMR spectra 
were integrated in order to assess the urinary excretion of these metabolites 7 days 
and 60 days after diet switch in LFD, HFD, NR and SR groups. For each metabolite, the 
integral at 7 days and 60 days was divided by the integral at day 0 (during the pre 
intervention period) in order to normalise the urinary excretion of these metabolites 
25 according to the baseline. The ratio obtained for each metabolite was compared 
between LFD, HFD, NR and SR groups at each timepoint using non parametric Mann 
and Whitney test. 
Major findings and highlights: 
18 
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Weight gain variability in CS7BL/6J mice fed a HFD. 
In order to study the contribution of diets to the development of obesity, 60 
C57BL/6J mice were fed with a chow diet (CHO) during a pre-intervention period of 1 
week, followed by a diet switch where mice were fed with a LFO (n=20) or a HFO 
5 (n=40) for 60 days. Body weight was measured during the pre-intervention period 
and 7 and 60 days after the diet switch (Figure LA). Weight monitoring showed a 
significant increase of weight in HFO fed mice compared to LFO fed mice through the 
experiment. In particular, the average weight of HFO fed mice was 1.5 g higher (p = 
3.9 x 10-7) at 7 days and 4.5 g higher (p = 2.36 x 10-8 ) at 60 days than control mice. The 
10 weight distribution also revealed a strong heterogeneity among the HFO group at 7 
days (coefficient of variation CV = 0.05), which was even more noticeable at 60 days 
(CV = 0.120) (Figure loB). This observation highlights the existence of a strong 
phenotypic variability within the HFO group and suggests the existence of specific 
metabolic signatures associated to these obese-sub phenotypes. 
15 
In order to characterize the "Strong-Responder" (SR) and "Non-Responder" (NR) to 
HF feeding, we stratified the mouse population according to body weight gain (BWG) 
after 7 days and 60 days of HF feeding. Mice being consistently at the top and the 
bottom thirds of the BWG distribution were designated as NR and SR mice 
20 respectively with the exception of 3 SR mice being in the top half of BWG distribution 
at 60days. This threshold was selected in order to obtain enough samples in each 
group (NR mice n=10 SR mice=14) and perform powerful statistical tests as well as to 
identify significant difference in metabolic signatures between these two groups. The 
average weight trajectory of NR, SR and LF fed mice over time (Figure 1.0) revealed 
25 that SR mice gained significantly more weight than NR mice and LF fed mice during 
the experiment. Interestingly, there was no significant difference in body weight 
between the NR group and the LFO group at 7 days (p = 0.10), but we identified a 
significant variation in body weight at 60 days (p = 7.67 x 10-5). In addition, the body 
weight gain trajectory of NR mice (regression coefficient=3.85) was similar with LF fed 
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mice highlighting that the weight gain behaviour of NR mice was comparable to LF 
mice overtime, whereas SR mice tend to accumulate weight faster. This early and 
sustained inflexion of body weight gain trajectory, defining strong responder and 
non-responder subgroups suggests the existence of a differential predisposition to 
5 diet induced obesity (010) in C57BL/6J mice. Hence, we will test in this study the 
ability to predict weight gain trajectories in HFO-fed mice based on early metabolic 
profiles. 
Urine metabolic profiling points out sustained metabolic signature associated to 
10 high fat induced obesity 
To investigate the specific metabolic signature associated with diet-induced obesity 
development, we acquired urine metabolic profiles 1 week before, 7 and 60 days 
after the dietary intervention using lH NMR spectroscopy (Figure 2.A, 2.B). Urine 
metabolic profiles from LF and HF fed mice were then compared at each time point 
15 by using OPLS-OA models. Each model was calculated by using one predictive and 
several orthogonal components. The optimal number of orthogonal components was 
determined by R2y and Q2y goodness-of-fit statistics. The OPLS-OA score plots for 
models at 7 days (Figure 2.C) and 60 days (Figure 2.0) showed that the strong 
metabolic variation associated with to HF feeding was highlighted along the 
20 predictive component (Tpred) whilst the second axis illustrating the first orthogonal 
component (Torth) reflects within group variability linked to diet-independent 
effects. 
For each model, the metabolites with the highest correlation coefficient were 
25 identified and summarised in a heatmap (Figure2.E) indicating the urinary metabolic 
variations between LF and HF mice. Specifically, the level of carnitine, 
hexanoylglycine, and the intermediates of BCAAs oxidation (isovalerylglycine, a-keto-
~methylvalerate and a-ketovalerate) were significantly increased in the HF group at 7 
days and 60 days. Conversely, the levels of methylamine derivatives produced from 
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microbial choline metabolism (trimethylamine (TMA), and trimethylamine-N-oxide 
(TMAO)) as well as the end-product of phenylalanine degradation by gut bacteria 
(phenylacetylglycine) were decreased in the HF group during the whole experiment. 
In particular, the degree of variation in the urinary level of TMAO between 7 days and 
5 60 days suggests a time-dependent shift in the conversion of TMA to TMAO under 
HFD feeding. Hence, HFD treatment may imply significant changes in gut microbiota 
activity. Time dependent metabolic adaptation to HFD feeding was also characterized 
by a significant reduction of indoxylsulfate in urine of mice fed a HF for 7 days. End 
products of Nicotinamide adenine dinucleotide (Nicotinamide adenine dinucleotide) 
10 pathways (Nl-methyl-2-pyridone-5-carboxamide : 2PY and Nl-methyl-4-pyridone-3-
carboxamide: 4PY) were also positively correlated with mice fed a HF for 60 days. The 
excretion of isovalerylglycine, a-keto-~-methylvalerate and a-ketoisovalerate 
significantly and consistently increased in HFD fed group compared to LFD fed group 
overtime, so they constitute qualitative and stable candidate biomarkers of DIO. 
15 
Urine metabolic profiling of NR and SR mice highlights a specific metabolic 
adaptation associated to obesity prone and obesity resistant phenotype 
The establishment of metabolic profiles of SR and NR mice enabled to identify 
metabolites associated with the highest divergence in weight gain. Comparisons of IH 
20 NMR spectral data between NR and SR were performed using pair wise OPLS-DA 
models at 7 days and 60 days (Figure 3.A, 3.B). OPLS-DA score plot at 7 days (Figure 
3.C), and 60 days (Figure 3.D) displayed a good discrimination between NR and SR 
mice along the predictive component (Tpred). The second axis illustrates orthogonal 
variation to strong obesity-associated-response. Interestingly, no difference in 
25 urinary metabolic profiles of NR and SR mice were identified before the diet switch, 
which highlights that C57BL/6J mice all have similar phenotypes and metabotypes 
when they were fed a chow diet. 
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The heatmap (Figure 3.E) summarizing metabolites involved in the group separation 
displayed differential metabolic profiles associated with NR and SR mice during a 
short-term period (7 days) and a long-term period (60 days) of HF feeding. In 
particular, a specific metabolic signature involving leucine catabolism, ~ oxidations, 
5 and short chain fatty acid productions, were associated with the gradation of obesity. 
Indeed, hexanoylglycine, isovalerylglycine, leucine, acetate and isobutyrate were 
negatively correlated with SR mice during the overall experiment. As these 
metabolites are consistently down-regulated in SR mice, they constituted the stable 
candidate marker of obesity-resistant phenotype. The comparison of metabolic 
10 profiles between SR and NR mice at 7 days and 60 days also showed a time 
dependant metabolic signature associated with phenotype variability. A lower urinary 
excretion of acetate was observed in SR mice after 7 days of HFD. By contrast, a 
higher urinary excretion of sucrose was noticed in SR mice at the same period. 
Surprisingly, taurine was positively correlated with SR mice 7days after of HF feeding 
15 and negatively correlated with SR mice after 60 days. The urine metabolic profile of 
SR mice after 60 days of HFD was also marked by an increase of creatine, 
guanidoacetate, tartrate, hippurate, and hydroxyphenylacetylglycine. Interestingly, 
hexanoylglycine and isovalerylglycine, which were characterised as qualitative 
candidate markers of DID, were also identified as stable candidate marker of obesity-
20 resistant phenotype. These results pointed out that leucine catabolism and ~ 
oxidation taking place in the mitochondria are strongly affected with HF feeding and 
their specific regulation might contribute in the onset of obesity. 
Urinary exertion patterns of several metabolites pointed out specific deregulations 
25 of mitochondrial metabolism in HF mice and SR mice. 
The regulation of mitochondrial metabolism in HFD fed mice was further investigated 
with the help of a complementary univariate data analysis approach (cf method). 
Urinary excretion of ~ oxidation intermediates: hexanoylglcyine, carnitine and 
acylcarnitine were consistently increased in urine of HF fed mice compared to LF fed 
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mice which suggests an increase of fatty acid overflow in the mictochondria and an 
activation of ~ oxidation. The end product of Nicotinamide adenine dinucleotide 
pathways (2PY, 4PY) also constantly increased in mouse urine after HFD feeding 
which indicates an up-regulation of beta oxidation and peroxidome proliferators. The 
5 integrations confirmed that leucine, valine, isoleucine as well as intermediates of 
BCAAs catabolism(isovalerylglycine, a-keto-~methylvalerate and a-ketovalerate) 
were significantly and consistently increased in HF fed mice supporting the 
hypothesis of HFD associated up-regulation of BCAAs catabolism. Krebs's cycle was 
also partly regulated in HF fed mice as we observed a short term urinary increase of 
10 succinate in mouse 7 days after HFD, and constant in urine of HF fed mice compared 
to LF fed mice. These results support the hypothesis that valine and isleucine 
catabolism is up-regulated inducing the formation of succinyl-CoA and the production 
of the following Krebs's cycle intermediates. Surprisingly, the other Krebs's cycle 
intermediates (citrate, cis-aconitase, a-ketoglutarate) were not significantly different 
15 between LF and HF fed mice suggesting a disconnection between leucine catabolism 
and beta oxidation producing acetyl-CoA, and Krebs's cycle. Specific metabolic 
regulations could divert the flux of acetyl-CoA toward other metabolic pathways. In 
particular, the increased level of vinylaceylglycine in urine of HF fed mice suggests 
that acetyl-Coa could be redirected toward acetoacetyl-CoA which is linked to 
20 butanoate metabolism and the formation of vinylacetylglycine. These results confirm 
that HFD induce an up-regulation of mitochondrial oxidative pathways and Krebs's 
cycle which might lead to an increase of energy production. 
Univariate data analysis also enabled us to better understand the link between ~ 
25 oxidation, BCAAs catabolism and Krebs's cycle in the context of phenotype variability. 
Integrations of BCAAs catabolism intermediates showed that only isovalerylglycine 
was significantly higher in urine of NR mice compared to SR mice or LF mice indicating 
that obesity-resistant mice were associated with disruption of leucine catabolism 
exclusively. Hexanoylglycine was significantly higher in urine of NR mice compared to 
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SR mice during the overall experiment whereas the urinary excretion of carnitine and 
acylcarnitine stayed unchanged. Hence, even though ~ oxidation seemed to be 
affected in NR mice, fatty acid flow toward the mitochondria is consistent between 
NR and SR mice. In addition, we observed a significant increase of vinylacetylglycine 
5 in urine of NR mice suggesting a redirection of acetyl-coA toward the butanoate 
metabolism. Interestingly, no difference in Krebs's cycle activity between NR and SR 
mice were observed after 7 days of HFD. At 60 days, succinate, were significantly 
higher in urine of SR mice highlighting a up-regulation of Krebs's cycle. As previously 
observed, the urinary excretion of other Krebs's cycle intermediates (citrate, a-
10 ketoglutarate, cis-aconitate) were unchanged between NR and SR mice supporting 
the hypothesis of specific regulation within the Krebs's cycle. Our results indicate that 
after a long term period of HFD, obesity prone mice are associated with an 
impairment of energy metabolism which is characterised by a deregulation of Krebs's 
cycle. The rapid activation of ~ oxidation, leucine catabolism and butanoate 
15 metabolism in obesity resistant mice may be a protective mechanism against fatty 
acid overflow which enable to maintain energy homeostasis. 
Relationships of the highlighted metabolites with weight gain was assessed using 
metabolite urinary concentration (as measured by IH NMR spectroscopy), fold of 
20 change from baseline (TO), and ratio with urinary creatine (as measured by IH NMR 
spectroscopy). Emphasis was given on the capcity to predict weight gain and stratify 
individuals as NR or SR, based on the short term metabolic response to the dietary 
challenge (namely at T7). The correlation coefficients values are summarized in Table 
1, whilst the fold of changes are reported in table 2. To select the more robust 
25 markers, there was used the % Mean decrease accuracy of 'out-of-bag' data as 
variable importance feature. In this way, it was possible to determine the variables 
that better discriminate subjects according to their weight gain susceptibility (NR and 
SR phenotypes, Figure 5), indicating hexanoylgycine, siovaleroylglycine, TMAO and 
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acetate as the most robust metabolic markers for stratifying subjects as NR or SR 
phenotypes. 
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Claims 
1. Biomarker, wherein the biomarker is isovalerylglycine. 
2. Use of isovalerylglycine as a biomarker in urine for detecting and/or 
quantifying the likelihood to resist high fat diet induced weight gain. 
5 3. Method of diagnosing the likelihood of a subject to resist high fat diet induced 
10 
weight gain, comprising 
determining the level of isovalerylglycine in a urine sample previously 
obtained from a subject to be tested, and 
- comparing the subject's isovalerylglycine level to a predetermined 
reference value, 
wherein the predetermined reference value is based on an average 
isovalerylglycine level in urine in a control population, and 
wherein an increased isovalerylglycine level in the sample compared to the 
predetermined reference value indicates an increased likelihood to resist high 
15 fat diet induced weight gain. 
20 
4. The method of claim 3, further comprising the steps of 
- determining the level of at least one further biomarker selected from the 
group consisting of hexanoylglycine, trimethylamine-N-oxide, leucine, 
isobutyrate, acetate, guanidoacetate, sucrose, tartaric acid, hippuric acid 
and hydroxyphenylacetylglycine in the urine sample, and 
- comparing the subject's level of the at least one further biomarker to a 
predetermined reference value, 
wherein the predetermined reference value is based on average levels of that 
at least one further biomarker in a urine sample of a normal healthy control 
25 population, and 
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wherein an increased hexanoylglycine, leucine, acetate, isobutyrate, and/or a 
decreased trimethylamine-N-oxide, guanidoacetate, sucrose, tartaric acid, 
hippuric acid and/or hydroxyphenylacetylglycine level in the urine sample 
compared to the predetermined reference values indicates an increased 
5 likelihood to resist high fat diet induced weight gain. 
5. The method in accordance with one of claims 3 to 4, wherein the levels of the 
biomarkers are determined by IH-NMR and/or mass spectrometry in the 
sample and in the reference. 
10 6. The method in accordance with one of claims 3 to 5, wherein a decreased 
likelihood to resist high fat diet induced weight gain is indicative for the 
likelihood to develop disorders associated with overweight and/or obesity. 
7. The method in accordance with claim 6, wherein the disorders associated with 
overweight and/or obesity are cardio metabolic diseases and/or metabolic 
15 deregulations. 
8. The method in accordance with one of claims 3 to 7, to be carried out on 
underweight, normal, overweight or in obese subjects. 
9. The method in accordance with one of claims 3 to 8, wherein the subject is a 
human or a companion animal such as a cat or a dog. 
20 10. The method in accordance with one of claims 3 to 8, wherein a decreased 
likelihood to resist high fat diet induced weight gain is indicative for a lack of 
specific activation of mitochondrial oxidative pathways. 
11. The method in accordance with one of claims 3 to 8, wherein an increased 
likelihood to resist high fat diet induced weight gain is indicative for a specific 
25 activation of mitochondrial oxidative pathways. 
27 
WO 2014/086605 PCT/EP2013/074570 
12. The method in accordance with one of claims 1Q-11, wherein the 
mitochondrial oxidative pathways are selected from the group consisting of ~ 
oxidation, butanoate metabolism and leucine catabolism. 
13. The method in accordance with one of claims 3 to 12 wherein the subject is a 
5 child, a teenager, a young adult and/or a person at risk of developing 
overweight or obesity. 
10 
14. The method in accordance with one of claims 3 to 13 wherein the method is 
used to devise a stratified diet for a specific group of subjects or a personalized 
diet for a specific subject. 
28 
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